Astellas licenses Vical vax for $130M

Japan's Astellas will pay up to $130 million to license a vaccine to prevent cytomegalovirus (CMV) reactivation in transplant recipients. The disease is typically dormant in those who are healthy but can cause illness in immunocompromised people. A Phase III trial of TransVax in hematopoietic stem cell transplant recipients and a Phase II study in solid organ transplant patients are slated to begin in 2012. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.